ATE546734T1 - Risikomarker für eine herzkreislaufkrankheit - Google Patents

Risikomarker für eine herzkreislaufkrankheit

Info

Publication number
ATE546734T1
ATE546734T1 AT04817973T AT04817973T ATE546734T1 AT E546734 T1 ATE546734 T1 AT E546734T1 AT 04817973 T AT04817973 T AT 04817973T AT 04817973 T AT04817973 T AT 04817973T AT E546734 T1 ATE546734 T1 AT E546734T1
Authority
AT
Austria
Prior art keywords
cardiovascular disease
subject
methods
risk
oxidized
Prior art date
Application number
AT04817973T
Other languages
English (en)
Inventor
Stanley Hazen
Marc Penn
Jonathan Smith
Renliang Zhang
Lemin Zheng
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Application granted granted Critical
Publication of ATE546734T1 publication Critical patent/ATE546734T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Electrochemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
AT04817973T 2003-12-05 2004-12-06 Risikomarker für eine herzkreislaufkrankheit ATE546734T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52717803P 2003-12-05 2003-12-05
US60052704P 2004-08-11 2004-08-11
US60055104P 2004-08-11 2004-08-11
US61904404P 2004-10-15 2004-10-15
PCT/US2004/040766 WO2005055810A2 (en) 2003-12-05 2004-12-06 Risk markers for cardiovascular disease

Publications (1)

Publication Number Publication Date
ATE546734T1 true ATE546734T1 (de) 2012-03-15

Family

ID=34682352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04817973T ATE546734T1 (de) 2003-12-05 2004-12-06 Risikomarker für eine herzkreislaufkrankheit

Country Status (8)

Country Link
US (4) US7781219B2 (de)
EP (2) EP1697746B1 (de)
JP (2) JP4625812B2 (de)
AT (1) ATE546734T1 (de)
AU (1) AU2004296829A1 (de)
CA (1) CA2549236C (de)
ES (1) ES2381551T3 (de)
WO (1) WO2005055810A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
WO2006014628A1 (en) * 2004-07-19 2006-02-09 University Of Washington Methods for assessing the risk for development of cardiovascular disease
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AP2008004634A0 (en) * 2006-03-23 2008-10-31 Emelta De Guzman Breyer Apolipoprotein fingerprinting technique
US20070238183A1 (en) * 2006-04-04 2007-10-11 Stout Robert L Methods for assessment of cardiovascular disease risk
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
DK2482078T3 (en) 2006-05-01 2016-05-02 Critical Care Diagnostics Inc Cardiovascular disease diagnosis
US7972794B2 (en) * 2006-07-18 2011-07-05 Quest Diagnostics Investments Incorporated Oxidized apoA-I determination by mass spectrometry
FI20075245A0 (fi) 2007-04-11 2007-04-11 Markku Ahotupa Menetelmä oksidatiivisen metabolian arvioimiseksi
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
US20090208992A1 (en) * 2008-02-20 2009-08-20 The Cleveland Clinic Foundation Paraoxonase 1 enzymatic activity, a risk indicator for major adverse cardiovascular events
WO2009114875A2 (en) * 2008-03-14 2009-09-17 The Cleveland Clinic Foundation Oxidized paraoxonase 1 and paraoxonase 1/hdl particle number ratio as risk markers for cardiovascular disease
PT3093663T (pt) 2008-04-18 2018-10-19 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
US20110034419A1 (en) * 2009-06-27 2011-02-10 Musc Foundation For Research Development Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease
RU2410017C1 (ru) * 2009-07-22 2011-01-27 Федеральное государственное учреждение "Московский научно-исследовательский онкологический институт им. П.А. Герцена" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "МНИОИ им. П.А. Герцена" Минздравсоцразвития России) Способ оценки риска развития периоперационных сердечно-сосудистых осложнений при внесердечных хирургических вмешательствах
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
EP2568294B1 (de) * 2009-11-13 2015-01-07 BG Medicine, Inc. Risikofaktoren Und Vorhersage Von Myokardinfarkt
US20110245650A1 (en) * 2010-04-02 2011-10-06 Kerwin William S Method and System for Plaque Lesion Characterization
WO2012145037A1 (en) * 2011-04-19 2012-10-26 Scott & White Healthcare Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease
US20140162376A1 (en) * 2011-04-29 2014-06-12 Michael N. Oda Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport
US9322833B2 (en) * 2011-06-16 2016-04-26 Children's Hospital & Research Center At Oakland Ultra-small ApoB-containing particles and methods of use thereof
WO2013176694A1 (en) 2012-05-22 2013-11-28 Berg Pharma Llc Interrogatory cell-based assays for indentifying drug-induced toxicity markers
IN2015DN01767A (de) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
US10352947B2 (en) * 2012-09-12 2019-07-16 Berg Llc Use of markers in the identification of cardiotoxic agents and in the diagnosis and monitoring of cardiomyopathy and cardiovascular disease
JP6231307B2 (ja) * 2013-06-27 2017-11-15 中野 恵正 機能不全ｈｄｌの測定方法、機能不全ｈｄｌ測定用キット、並びに、生活習慣病マーカーの測定方法
US9638699B2 (en) 2013-07-18 2017-05-02 The University Of Sydney Biomarkers of oxidative stress
US10126308B2 (en) * 2014-02-17 2018-11-13 Arizona Board Of Regents On Behalf Of Arizona State University Methods for assessing biospecimen integrity
WO2015123338A2 (en) * 2014-02-17 2015-08-20 Arizona Board Of Regents On Behalf Of Arizona State University Methods for assessing biospeciment integrity
RU2016144908A (ru) 2014-05-02 2018-06-05 Серени Терапеутикс Холдинг Са Маркеры hdl-терапии
EP4159754A1 (de) 2014-05-15 2023-04-05 Cleveland Heartlab, Inc. Zusammensetzungen und verfahren für reinigung und nachweis von hdl und apoa1
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
CA2968221A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
AU2016272252B2 (en) * 2015-05-29 2017-09-28 Sysmex Corporation Method for measuring cholesterol uptake capacity of lipoproteins and reagent kit thereof
CN109068987B (zh) 2016-04-01 2022-03-22 心脏起搏器股份公司 用于生理事件检测的警报管理
EP3488241B1 (de) 2016-07-21 2025-02-26 Cleveland Heartlab, Inc. Detektion hdl-assoziierter proteinbiomarkertafeln
US20190367600A1 (en) * 2017-01-27 2019-12-05 A-Clip Institute, Co., Ltd. Prophylactic and/or therapeutic agent of infectious diseases or inflammatory diseases
US11942219B1 (en) * 2017-09-25 2024-03-26 Cerner Innovation, Inc. Determining a cardiovascular ischemic event and decision support tool
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US11054389B2 (en) * 2018-03-19 2021-07-06 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2020036987A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
JP7193082B2 (ja) * 2018-12-28 2022-12-20 サンスター株式会社 血管組織機能低下リスクマーカー
RU2718290C1 (ru) * 2019-02-05 2020-04-01 Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) Способ определения операбельности больных раком пищевода
RU2754946C1 (ru) * 2020-04-03 2021-09-08 Федеральное государственное бюджетное военное образовательное учреждение высшего образования "Военно-медицинская академия имени С.М. Кирова" Министерства обороны Российской Федерации (ВМедА) Способ определения риска наличия кальциноза клапана аорты у пациентов 60 лет и старше

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4302386A (en) 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4105776A (en) 1976-06-21 1978-08-08 E. R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4316906A (en) 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4508729A (en) 1979-12-07 1985-04-02 Adir Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4337201A (en) 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US4410520A (en) 1981-11-09 1983-10-18 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
GB2128984B (en) 1982-05-12 1985-05-22 Hoffmann La Roche Diaza-bicyclic compounds
US4780401A (en) 1984-04-09 1988-10-25 Ciba-Geigy Corporation Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications
US4845079A (en) 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
US5066643A (en) 1985-02-19 1991-11-19 Sandoz Ltd. Fluorine and chlorine statine or statone containing peptides and method of use
US4894437A (en) 1985-11-15 1990-01-16 The Upjohn Company Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4772684A (en) 1987-01-20 1988-09-20 Triton Biosciences, Inc. Peptides affecting blood pressure regulation
US4980283A (en) 1987-10-01 1990-12-25 Merck & Co., Inc. Renin-inhibitory pepstatin phenyl derivatives
US5089471A (en) 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
US5034512A (en) 1987-10-22 1991-07-23 Warner-Lambert Company Branched backbone renin inhibitors
US5063207A (en) 1987-10-26 1991-11-05 Warner-Lambert Company Renin inhibitors, method for using them, and compositions containing them
US5055466A (en) 1987-11-23 1991-10-08 E. R. Squibb & Sons, Inc. N-morpholino derivatives and their use as anti-hypertensive agents
US5081127A (en) 1988-01-07 1992-01-14 E. I. Du Pont De Nemours And Company Substituted 1,2,3-triazole angiotensin II antagonists
US5036054A (en) 1988-02-11 1991-07-30 Warner-Lambert Company Renin inhibitors containing alpha-heteroatom amino acids
US5036053A (en) 1988-05-27 1991-07-30 Warner-Lambert Company Diol-containing renin inhibitors
US5846799A (en) 1988-06-14 1998-12-08 La Region Wallone Human myeloperoxidase and its therapeutic application
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5106835A (en) 1988-12-27 1992-04-21 American Cyanamid Company Renin inhibitors
DE4004820A1 (de) 1989-08-05 1991-04-25 Bayer Ag Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln
US5064825A (en) 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
US5063208A (en) 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US5098924A (en) 1989-09-15 1992-03-24 E. R. Squibb & Sons, Inc. Diol sulfonamide and sulfinyl renin inhibitors
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5073566A (en) 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5064965A (en) 1990-03-08 1991-11-12 American Home Products Corporation Renin inhibitors
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
US5075451A (en) 1990-03-08 1991-12-24 American Home Products Corporation Pyrrolimidazolones useful as renin inhibitors
US5085992A (en) 1990-07-19 1992-02-04 Merck & Co., Inc. Microbial transformation process for antihypertensive products
US5604105B1 (en) 1990-10-12 1999-08-24 Spectral Diagnostics Inc Method and device for diagnosingand distinguishing chest pain in early onset thereof
US5087634A (en) 1990-10-31 1992-02-11 G. D. Searle & Co. N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5071837A (en) 1990-11-28 1991-12-10 Warner-Lambert Company Novel renin inhibiting peptides
US5122534A (en) 1991-02-08 1992-06-16 Pfizer Inc. Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
JP3370334B2 (ja) * 1993-09-29 2003-01-27 栄次 松浦 酸化リポタンパク質の測定法およびその用途
WO1996004311A1 (en) 1994-08-03 1996-02-15 University Of Alabama At Birmingham Research Foundation Monoclonal antibody to nitrotyrosine, methods for diagnosis and methods for treatment of disease
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE69512930T2 (de) 1994-10-27 2000-05-18 Merck Frosst Canada & Co., Halifax Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
JP3436444B2 (ja) * 1995-07-21 2003-08-11 ヤマサ醤油株式会社 酸化ｈｄｌの測定法及びキット
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
TW442286B (en) 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6268220B1 (en) 1996-09-09 2001-07-31 Washington University Diagnostic method for atherosclerosis
US5731208A (en) 1996-09-09 1998-03-24 Washington University Method of detecting conditions indicative of atherosclerosis
WO1998043630A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6133039A (en) 1998-02-09 2000-10-17 Washinton University In vivo method for determination of oxidative stress
US6096556A (en) 1998-02-09 2000-08-01 Washington University Method for the determination of oxidative stress
US5962636A (en) 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
AUPQ429399A0 (en) * 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
WO2002038609A2 (en) 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
ES2375268T3 (es) 2000-12-14 2012-02-28 The Brigham And Women's Hospital, Inc. Marcadores inflamatorios para la detección y prevención de diabetes mellitus.
BE1013881A6 (fr) 2000-12-21 2002-11-05 Univ Bruxelles Fractions de ldl oxydees, procede d'obtention et utilisation a but diagnostique ou therapeutique.
US7780950B2 (en) 2002-01-02 2010-08-24 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
DK1353666T3 (da) 2001-01-02 2013-10-14 Cleveland Clinic Foundation Myeloperoxidase, en risikoindikator for cardiovasculær sygdom
US20030008373A1 (en) 2001-04-17 2003-01-09 Myriad Genetics, Incorporated APOA1-interacting proteins and use thereof
US20040241744A1 (en) * 2001-07-12 2004-12-02 Hiroaki Kohno Method of quantifying denatured lipoprotein, reagents for quantifying denatured lipoprotein, method of detecting circulatory disease and reagents for detecting circulatory disease
US7476551B2 (en) 2001-08-27 2009-01-13 The Board Of Trustees Of The University Of Arkansas Diagnosing atherosclerosis risk by measuring carbamylated low density lipoprotein levels
EP1428022A1 (de) * 2001-09-12 2004-06-16 National Research Council of Canada Ein verfahren zum simultanen und direkten nachweis von serumcholesterol in hdl und ldl mittels infrarot spektroskopie
US20030119792A1 (en) 2001-09-28 2003-06-26 Roca Manuel Merlos Method of inhibiting the production and/or effects of intestinal pro-inflammatory cytokines, prostaglandins and others
US7320806B2 (en) * 2002-09-09 2008-01-22 Vdf Futureceuticals, Inc. Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation
EP1706131A4 (de) 2003-12-15 2009-08-12 Univ California Den zellulären cholesterin-efflux stimulierende helikale synthetische peptide
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
AU2005233583B2 (en) 2004-04-08 2011-02-03 Sangamo Therapeutics, Inc. Methods and compositions for modulating cardiac contractility
US7833795B2 (en) 2004-08-24 2010-11-16 The Trustees Of The University Of Pennsylvania Assessment of cardiovascular risk using isoprostane biomarkers and COX-2 selective inhibitors

Also Published As

Publication number Publication date
JP4625812B2 (ja) 2011-02-02
US20150037905A1 (en) 2015-02-05
JP2011002460A (ja) 2011-01-06
EP1697746B1 (de) 2012-02-22
EP2306192B1 (de) 2015-10-14
US7781219B2 (en) 2010-08-24
EP1697746A2 (de) 2006-09-06
EP1697746A4 (de) 2007-08-29
CA2549236A1 (en) 2005-06-23
EP2306192A2 (de) 2011-04-06
AU2004296829A1 (en) 2005-06-23
ES2381551T3 (es) 2012-05-29
EP2306192A3 (de) 2011-08-10
US8722344B2 (en) 2014-05-13
WO2005055810A2 (en) 2005-06-23
US20100183607A1 (en) 2010-07-22
CA2549236C (en) 2017-06-13
JP2007515632A (ja) 2007-06-14
US9005904B2 (en) 2015-04-14
US8338110B2 (en) 2012-12-25
US20130177551A1 (en) 2013-07-11
WO2005055810A3 (en) 2005-12-08
US20050239136A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2005055810A3 (en) Risk markers for cardiovascular disease
Jakobson et al. Time tagging: A key to musicians' superior memory
DE60326214D1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
DE60325617D1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
DE60138829D1 (de) Verfahren zur unterscheidung des reizkolons von der entzündlichen darmerkrankung (inflammatory bowel disease, ibd) und zur überwachung von patienten mit ibd unter verwendung von endogenem gesamt-lactoferrin als marker
DE60207979D1 (de) Verfahren und Vorrichtung zur Bestimmung der Gewebespezifität von freier DNA in Körperflüssigkeiten
ATE278805T1 (de) Verfahren zur quantifizierung von cholesterol in lipoproteinen und quantifizierungsreagenzien
ATE281649T1 (de) Nachweis und bestimmung von stufen der coronaren arterienerkrankung
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
EP2177908A3 (de) Mit Diabetes assoziierte Marker und Verfahren zur Verwendung davon
ATE290375T1 (de) Verwendung eines mittels zur verminderung des risikos kardiovaskulärer erkrankungen
DE60315373D1 (de) Vorrichtung und Verfahren zur Bestimmung der Konzentration von Analyten
EE05675B1 (et) Meetod konformse haiguse diagnoosimiseks v?i tuvastamiseks, selleks vajalik katsemenetlus, reaktiivikomplekt ning seade
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
ATE438860T1 (de) P1gf und flt-1 als prognostische parameter bei kardiovaskulären erkrankungen
GB0524110D0 (en) Biomarkers and methods for identification of agents useful in the treatment of affective disorders
DE60016242D1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
DE602004004775D1 (de) Verfahren zur Diagnose von Leberfibrose.
EA200701602A1 (ru) Способ прогнозирования психических заболеваний, например аутизма и церебрального паралича
ATE178357T1 (de) Nachweismethoden für c-raf-1-genes.5
DE60133510D1 (de) Automatisches Verfahren zur quantitativen Bestimmung und Überwachung von exogenem Hämoglobin in Vollblut, Blutplasma und Blutserum
ATE432997T1 (de) Therapieüberwachung für tumoren unter benutzung acc133 mrna
DE69903278D1 (de) Verfahren zur Diagnose oder zur Prognose von Alzheimer Krankheit: therapeutische Zusammensetzung zur Verhinderung oder zur Behandlung von Alzheimer Krankheit
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8